Overview
Chronic drug-induced renal disease refers to renal impairment caused by prolonged exposure to certain medications, often complicating existing renal conditions and necessitating careful monitoring and management to prevent further deterioration. 46Diagnosis
Assess glomerular filtration rate (eGFR) to identify renal impairment 14.
Evaluate lipid profiles, particularly LDL-C levels, in patients on specific therapies like evolocumab 1.
Monitor for signs of microvascular thrombosis and hemostatic abnormalities through laboratory tests and imaging 7.
Consider body lead stores and urate excretion in patients with chronic renal disease, especially those with gout 5.Management
First-line treatments:
- Dietary protein restriction to reduce glomerular hypertension and slow disease progression 4.
- Antihypertensive therapy to manage blood pressure and alleviate glomerular hypertension 4.
Adjunctive treatments:
- Statins or PCSK9 inhibitors (e.g., evolocumab) for managing hypercholesterolemia in patients with chronic renal disease, particularly those with familial hypercholesterolemia 1.
- Management of urate levels in patients with gout and renal insufficiency 5.Special Populations
Pediatrics: Pediatric nephrologists should screen for adolescent health risk behaviors, including sexual health, given the impact of chronic renal disease on development 3.
Elderly: Specific considerations for elderly patients are not detailed in the provided abstracts, but general principles of managing renal impairment apply with caution due to polypharmacy risks.
Comorbidities: Patients with comorbid conditions like diabetes or those with solitary/remnant kidneys require tailored management focusing on controlling glomerular hypertension and hyperfiltration 4.Key Recommendations
Implement dietary protein restriction to mitigate progressive renal damage in chronic renal disease patients (Evidence: Strong 4).
Use antihypertensive therapy to manage glomerular hypertension and slow disease progression (Evidence: Strong 4).
Prescribe lipid-lowering agents like evolocumab cautiously in patients with chronic renal disease and familial hypercholesterolemia, monitoring for efficacy and safety (Evidence: Moderate 1).
Screen adolescent patients with chronic renal disease for sexual health and risk behaviors, considering the nephrologist as the primary provider (Evidence: Expert opinion 3).References
1 Goicoechea M, Álvarez V, Segarra A, Polaina M, Martín-Reyes G, Robles NR et al.. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO). Nefrologia 2022. link
2 Boulton FE. Thomas Addis, MD (1881-1949): Scottish-American clinical laboratory researcher, social activist and pioneer of renal medicine. Journal of nephrology 2011. link
3 Hergenroeder AC, Brewer ED. A survey of pediatric nephrologists on adolescent sexual health. Pediatric nephrology (Berlin, Germany) 2001. link
4 Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney international 1996. link
5 Lin JL, Huang PT. Body lead stores and urate excretion in men with chronic renal disease. The Journal of rheumatology 1994. link
6 Haboubi NY, Smith VJ, Coyne JD, Ackrill P. Nodular regenerative hyperplasia of the liver in a non-treated patient with mesangiocapillary glomerulonephritis. Histopathology 1991. link
7 Stricher GE. Microvascular thrombosis in the pathogenesis of chronic renal disease. L'Ateneo parmense. Acta bio-medica : organo della Societa di medicina e scienze naturali di Parma 1975. link